Molecular Inflammation Research Group, Department of Medical Biology, Faculty of Health Sciences, University of Tromsø, 9037 Tromsø, Norway.
Host Microbe Interaction Research Group, Department of Medical Biology, Faculty of Health Sciences, University of Tromsø, 9037 Tromsø, Norway.
Int J Mol Sci. 2017 Nov 14;18(11):2414. doi: 10.3390/ijms18112414.
Human polyomavirus 9 (HPyV9) was originally detected in the serum of a renal transplant patient. Seroepidemiological studies showed that ~20-50% of the human population have antibodies against this virus. HPyV9 has not yet been associated with any disease and little is known about the route of infection, transmission, host cell tropism, and genomic variability in circulating strains. Recently, the HPyV9 variant UF-1 with an eight base-pair deletion, a thirteen base-pair insertion and with point mutations, creating three putative Sp1 binding sites in the late promoter was isolated from an AIDS patient. Transient transfection studies with a luciferase reporter plasmid driven by HPyV9 or UF1 promoter demonstrated that UF1 early and late promoters were stronger than HPyV9 promoters in most cell lines, and that the UF1 late promoter was more potently activated by HPyV9 large T-antigen (LTAg). Mutation of two Sp1 motifs strongly reduced trans-activation of the late UF1 promoter by HPyV9 LTAg in HeLa cells. In conclusion, the mutations in the UF1 late promoter seem to strengthen its activity and its response to stimulation by HPyV9 LTAg in certain cells. It remains to be investigated whether these promoter changes have an influence on virus replication and affect the possible pathogenic properties of the virus.
人多瘤病毒 9(HPyV9)最初在肾移植患者的血清中被发现。血清流行病学研究表明,约 20-50%的人群对该病毒有抗体。HPyV9 尚未与任何疾病相关联,关于其感染途径、传播、宿主细胞嗜性和循环株的基因组变异性知之甚少。最近,从一名艾滋病患者中分离到了具有 8 个碱基缺失、13 个碱基插入和点突变的 HPyV9 变异株 UF-1,在晚期启动子中创造了三个假定的 Sp1 结合位点。用 HPyV9 或 UF1 启动子驱动的荧光素酶报告质粒进行的瞬时转染研究表明,在大多数细胞系中,UF1 早期和晚期启动子比 HPyV9 启动子更强,并且 UF1 晚期启动子更能被 HPyV9 大 T 抗原(LTAg)激活。Sp1 两个基序的突变强烈降低了 HeLa 细胞中 HPyV9 LTAg 对晚期 UF1 启动子的转录激活作用。总之,UF1 晚期启动子的突变似乎增强了其活性及其对 HPyV9 LTAg 刺激的反应性。这些启动子变化是否会影响病毒复制并影响病毒的可能致病特性仍有待研究。